Top

Published in:

01-06-2019 | Probiotics | Cochrane Digest

Mesalamine (5-ASA) for the prevention of recurrent diverticulitis (Review)

Authors: M. Carabotti, B. Annibale

Published in: Techniques in Coloproctology | Issue 6/2019

Excerpt

Background Mesalamine, or 5-aminosalicylic acid (5-ASA) has been studied for the prevention of recurrent diverticulitis. …

Carter F, Alsayb M, Marshall JK, Yuan Y (2017) Mesalamine (5-ASA) for the prevention of recurrent diverticulitis. Cochrane Database Syst Rev 10:CD009839PubMed

Stollman N, Smalley W, Hirano I, Institute Clinical Guidelines Committee AGA (2015) American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis. Gastroenterology 149(7):1944–1949CrossRefPubMed

Cuomo R, Barbara G, Pace F, Annese V, Bassotti G, Binda GA, Casetti T, Colecchia A, Festi D, Fiocca R, Laghi A, Maconi G, Nascimbeni R, Scarpignato C, Villanacci V, Annibale B (2014) Italian consensus conference for colonic diverticulosis and diverticular disease. United Eur Gastroenterol J 2(5):413–442CrossRef

Kruis W, Germer CT, Leifeld L, German Society for Gastroenterology, Digestive and Metabolic Diseases and The German Society for General and Visceral Surgery (2014) Diverticular disease: guidelines of the german society for gastroenterology, digestive and metabolic diseases and the german society for general and visceral surgery. Digestion 90(3):190–207CrossRefPubMed

Dirks K, Calabrese E, Dietrich CF, Gilja OH, Hausken T, Higginson A, Hollerweger A, Maconi G, Maaser C, Nuernberg D, Nylund K, Pallotta N, Ripolles T, Romanini L, Saftoiu A, Serra C, Wüstner M, Sporea I (2019) EFSUMB Position Paper: recommendations for Gastrointestinal Ultrasound (GIUS) in Acute Appendicitis and Diverticulitis. Ultraschall Med 40(2):163–175CrossRefPubMed

Kruis W, Kardalinos V, Eisenbach T, Lukas M, Vich T, Bunganic I, PokrotnieksJ Derova J, Kondrackiene J, Safadi R, Tuculanu D, Tulassay Z, Banai J, Curtin A, Dorofeyev AE, Zakko SF, Ferreira N, Björck S, Diez Alonso MM, Mäkelä J, Talley NJ, Dilger K, Greinwald R, Mohrbacher R, Spiller R (2017) Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Aliment Pharmacol Ther 46(3):282–291CrossRefPubMedPubMedCentral

Khan RMA, Ali B, Hajibandeh S, Hajibandeh S (2018) Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta-analysis with trial sequential analysis of randomized controlled trials. Colorectal Dis 20(6):469–478CrossRefPubMed

Severi C, Carabotti M, Cicenia A, Pallotta L, Annibale B (2018) Recent advances in understanding and managing diverticulitis. F1000Res. https://doi.org/10.12688/f1000research.14299.1 CrossRefPubMedPubMedCentral

Barbara G, Scaioli E, Barbaro MR, Biagi E, Laghi L, Cremon C, Marasco G, Colecchia A, Picone G, Salfi N, Capozzi F, Brigidi P, Festi D (2017) Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut 66(7):1252–1261CrossRefPubMed

10.

Cohen E, Fuller G, Bolus R, Modi R, Vu M, Shahedi K, Shah R, Atia M, Kurzbard N, Sheen V, Agarwal N, Kaneshiro M, Yen L, Hodgkins P, Erder MH, Spiegel B (2013) Increased risk for irritable bowel syndrome after acute diverticulitis. Clin Gastroenterol Hepatol 11(12):1614–1619CrossRefPubMedPubMedCentral

11.

Kruis W, Meier E, Schumacher M, Mickisch O, Greinwald R, Mueller R, German SAG-20 Study Group (2013) Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon- a placebo-controlled study. Aliment Pharmacol Ther 37(7):680–690CrossRefPubMed

12.

Tursi A, Brandimarte G, Elisei W, Picchio M, Forti G, Pianese G, Rodino S, D’Amico T, Sacca N, Portincasa P, Capezzuto E, Lattanzio R, Spadaccini A, Fiorella S, Polimeni F, Polimeni N, Stoppino V, Stoppino G, Giorgetti GM, Aiello F, Danese S (2013) Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease—a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 38(7):741–751CrossRefPubMed

13.

Cremon C, Carabotti M, Cuomo R, Pace F, Andreozzi P, Barbaro MR, Annibale B, Barbara G, on behalf of the REMAD Group (2019) Italian nationwide survey of pharmacologic treatments in diverticular disease: results from the REMAD registry. United Eur Gastroenterol J 7(6):815–824. https://doi.org/10.1177/2050640619845990 CrossRef

Title: Mesalamine (5-ASA) for the prevention of recurrent diverticulitis (Review)
Authors: M. Carabotti
B. Annibale
Publication date: 01-06-2019
Publisher: Springer International Publishing
Keywords: Probiotics
Colonoscopy
Diverticulitis
Published in: Techniques in Coloproctology / Issue 6/2019
Print ISSN: 1123-6337
Electronic ISSN: 1128-045X
DOI: https://doi.org/10.1007/s10151-019-02037-3

At a glance: The STEP trials

Springer Medicine

Mesalamine (5-ASA) for the prevention of recurrent diverticulitis (Review)

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2019

Practice parameters for the diagnosis and treatment of anal intraepithelial neoplasia (AIN) on behalf of the Italian Society of Colorectal Surgery (SICCR)

Optimized fistulectomy using the novel FiXcision® device: a technical feasibility study and evaluation of short term healing rates

Totally intracorporeal robotic en bloc resection for deep infiltrating endometriosis of the rectovaginal wall with natural orifice specimen extraction

Minimally invasive colorectal cancer procedures in patients with obesity: an interdisciplinary approach

The 118th Annual Scientific Meeting of the American Society of Colon and Rectal Surgeons

Correction to: Progression of anal intraepithelial neoplasia in HIV-positive individuals: predisposing factors